Press Releases

01.07.2019

CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery

01.03.2019

Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata

12.21.2018

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

12.20.2018

Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis

12.20.2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

12.18.2018

Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company

12.18.2018

Pfizer Invites Public to View and Listen to Webcast of January 29 Conference Call with Analysts

12.17.2018

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

12.14.2018

Pfizer Declares First-Quarter 2019 Dividend

12.14.2018

Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)

12.14.2018

Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

12.02.2018

Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting